LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

4.51 3.92

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.3

Максимум

4.63

Ключови измерители
By Trading Economics
Приходи	-23M -37M
Продажби	-20M 21M
EPS	-0.58
Марж на печалбата	-177.011
Служители	293
EBITDA	-17M -32M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+45.52% upside

Дивиденти
By Dow Jones
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	89M 276M
Предишно отваряне	0.59
Предишно затваряне	4.51

Настроения в новините

By Acuity

50%

174 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.05.2026 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Печалби

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Печалби

F&P Healthcare's Outlook Key for Investors -- Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19.05.2026 г., 22:02 ч. UTC

Печалби

ZTO Express (Cayman): Di Xu to Resign From Board

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19.05.2026 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19.05.2026 г., 21:37 ч. UTC

Печалби

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19.05.2026 г., 21:01 ч. UTC

Печалби

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19.05.2026 г., 20:58 ч. UTC

Печалби

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19.05.2026 г., 20:46 ч. UTC

Горещи акции

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19.05.2026 г., 20:43 ч. UTC

Пазарно говорене

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19.05.2026 г., 20:34 ч. UTC

Печалби

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q EPS 5c >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q Sales $1.4B >JHX

19.05.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5B

19.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19.05.2026 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

45.52% нагоре

12-месечна прогноза

Среден 6.33 USD 45.52%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

174 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.